Based upon these findings, some of the clinical trials employing oestrogen receptor blockers or aromatase inhibitors as endocrine therapeutic agents have currently been investigated in the patients with NSCLC. For instance, phase II clinical trials of combination therapy of epidermal growth factor ...
Based upon these findings, some of the clinical trials employing oestrogen receptor blockers or aromatase inhibitors as endocrine therapeutic agents have currently been investigated in the patients with NSCLC. For instance, phase II clinical trials of combination therapy of epidermal growth factor ...
Critically, the interaction of oestrogen with its receptors is also involved in disease, especially breast cancer, and it is for this reason that oestrogen antagonists and blockers of oestrogen synthesis have been sought, and used therapeutically with great success [2, 3]. Oestrogen acts by ...